
Updated Phase 2 data showed an 86% CNS response rate in evaluable patients with untreated brain metastases, while FDA feedback shaped a planned Phase 3 trial.
Black Diamond Therapeutics reported an 86% CNS response rate with silevertinib among evaluable patients with untreated brain metastases in its Phase 2 trial. The company also outlined a Phase 3 program after receiving feedback from the FDA.
The updated results, based on an October 7 data cutoff, covered 43 frontline patients with non-classical EGFR mutations. The full group had a 60% overall response rate and median progression-free survival of 15 months. Among 16 patients with untreated brain metastases, seven were evaluable for CNS response.
Black Diamond plans a global Phase 3 trial that could start in the second quarter of 2027. It is designed to enroll 300 patients with untreated brain metastases, comparing silevertinib with physician’s choice of osimertinib or afatinib. The company said FDA feedback included potential accelerated approval based on CNS response and potential full approval based on progression-free survival.
The FDA also said safety data from a sufficient number of patients receiving the planned 150-mg dose must be submitted before the Phase 3 trial opens. The company said preliminary data from the planned study are expected in 2028.
Black Diamond reported $102 million in cash, cash equivalents and investments as of September 30, which it expects to fund operations into the second half of 2028. Its third-quarter net loss was $10 million. BDTX shares closed Monday at $1.86, up 7.2% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.